The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 does not affect food intake in rats

DiBrog, Adrianne M.; Kern, Katherine A.; Mukherjee, Ashmita; Przybysz, Johnathan T.; Mietlicki‐Baase, Elizabeth G.

doi:10.1016/j.pbb.2022.173444

Cited by 3 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of galantamine on food intake and weight loss in our study are supported by the results of others which show reductions of food intake and body weight in obese high-fat diet-fed mice 30 , the streptozotocin-induced (STZ) rat model of diabetes 31 , and in galantamine-treated patients with dementia 32 . Of interest, treatment with specific α7nAChR agonists like GTS-21 do not seem to impact food intake or body weight 33 . However, like galantamine, vagal nerve stimulation (VNS) has also been shown to suppress appetite, increase circulating GLP-1 and decrease inflammation 34 – 36 .…”

Section: Discussionmentioning

confidence: 98%

Galantamine improves glycemic control and diabetic nephropathy in Leprdb/db mice

Meng,

Ma,

Suo

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Galantamine, a centrally acting acetylcholinesterase inhibitor, has been shown to attenuate inflammation and insulin resistance in patients with metabolic syndrome. We investigated the effects of galantamine on glycemic control and development of diabetic nephropathy (DN) in Leprdb/db mice. Galantamine significantly reduced food intake, body weight, blood glucose and HbA1c levels. Insulin resistance (HOMA-IR, QUICKI), HOMA-β and elevations in plasma inflammatory cytokine levels (TNF-α, IL-6 and HMGB-1) were all attenuated by galantamine. Galantamine also ameliorated diabetes-induced kidney injury as evidenced by improvements in renal function (BUN, creatinine, albuminuria), histologic injury and apoptosis. Improved glycemic control and nephropathy were associated with increased circulating GLP-1, decreased renal P-38 MAPK and caspase-1 activation and reduced SGLT-2 expression. These findings provide insights into the mechanisms by which galantamine improves glycemic control and attenuates DN in the Leprdb/db mouse model.

show abstract